Bromantane

Russian clinical studies suggest combined anxiolytic and mild stimulant properties, but Western peer-reviewed evidence is thin.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Approved in Russia (Ladasten) for neurasthenia. Proposed mechanism involves upregulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase gene expression. Western literature is sparse.

• Reported combined anxiolytic and activating effects
• May upregulate dopamine synthesis enzymes
• Does not appear to cause dependence in available data

Russian prescribing used 50–100 mg/day. Self-experimenters commonly report 25–100 mg.

• Headache
• Insomnia at higher doses
• Skin irritation (topical)

Banned by WADA. Not approved outside Russia. Long-term safety data is limited.

Most studies are in Russian-language journals and have not been independently replicated in Western settings.

• Anxiety50
• Focus45
• Energy45
• Mood40